Print  |  Close

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3


Active: Yes
Cancer Type: Lung Cancer NCT ID: NCT04429087
Trial Phases: Phase I Protocol IDs: 1438-0001 (primary)
NCI-2021-01392
2019-000729-31
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Boehringer Ingelheim Pharmaceuticals Inc
NCI Full Details: http://clinicaltrials.gov/show/NCT04429087

Summary

This study is open to adults with small cell lung cancer and other neuroendocrine cancers
that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with
advanced cancer for whom previous treatment was not successful or no standard treatment
exists.

The purpose of this study is to find out the highest dose of BI 764532 and the best
treatment schedule that people can tolerate. BI 764532 is an antibody-like molecule
(DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, BI
764532 is given to people for the first time. That means no clinical data are available
for BI 764532.

Participants get BI 764532 either weekly or once every 3 weeks. If there is benefit for
the participants and if they can tolerate it, the treatment is given for a maximum of 3
years. During this time, participants visit the study site about 20 times depending on
the response to the treatment. Doctors record any unwanted effects and regularly check
the general health of the participants.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.